Abstract:525 Objectives The mesenchymal epithelial transition (c-Met) factor overexpression has been widely accepted as a potent biomarker for various of cancers such as glioblastoma, breast cancer, colorectal cancer, etc. c-Met inhibitor, which targets c-Met and further interferes with downstream signaling pathways, could serve as both diagnostic and therapeutic molecule by specifically binding with c-Met receptors. Until now small molecule based probes for c-Met imaging has not been reported. In previous studies, we have successfully synthesized c-Met inhibitor C21b with high c-Met receptor binding and suppressing functions and validated its tumor suppression capability. In the present study, we aim to develop a 68Ga labeled, C21b based PET probe for imaging of c-Met positive tumors such as glioblastoma which realize the potential for both glioblastoma detection and cancer therapy evaluation. Methods C21b molecule with NODAGA chelator was obtained through chemical synthesis and confirmed by MS and 1H-NMR. The resulting conjugate NODAGA-C21b was radiolabeled with 68Ga in 0.1N sodium acetate (pH 5.5) at 55 oC within 15 min. The PET probe was then characterized by HPLC analysis and subjected to mouse serum stability assay. The cell uptake and binding affinity tests of 68Ga-NODAGA-C21b were conducted using U87MG glioblastoma cells. Small animal PET imaging and biodistribution analysis were conducted on mice with c-Met overexpression (U87MG) and low expression (OVCAR3) tumor xenograft models (n=4 per group) after injection of approximately 7.4 MBq of 68Ga-NODAGA-C21b for up to 2 h after injection. Results 68Ga-NODAGA-C21b was successfully synthesized in high radiochemical purify (>99%) and yield (>98%) and demonstrated high stability in mouse serum for up to 2 h incubation. U87MG cells showed increased uptake of 68Ga-NODAGA-C21b tracer with longer incubation time (from 9.6 % at 15 min to 14.2 % at 2 h incubation). The uptake could be effectively reduced by excess unlabeled C21b and c-Met inhibitor Crizotinib (14.2 % vs. 2.4 % and 2.3 % for self-blocking and Crizotinib blocking, respectively, after 2 h incubation). Binding affinity assays revealed the Kd was 2.88 nM for U87MG cells. Small animal PET/CT imaging showed that 68Ga-NODAGA-C21b accumulated in U87MG tumor and retained at similar level during the 2 h monitoring (0.63, 0.46 and 0.45 %ID/g at 30, 60 and 120 min post injection). However, in OVCAR3 tumor, the signal was significantly lower from beginning and decreased dramatically afterwards (0.47, 0.26 and 0.20 %ID/g at 30, 60 and 120 min post injection). Biodistribution results exhibited that Tumor/Muscle (T/M) signal ratio increased from 3.18 to 4.15 in U87MG model at 2 h post injection time point while T/M ratio decreased from 2.29 to 1.66 in OVCAR3 model. And Tumor/Brain (T/B) signal ratio was higher in U87MG model than that of in OVCAR3 model at all three time points (2.53 vs. 1.56, 2.37 vs. 1.36 and 2.39 vs. 1.85). The probe was found to be mainly metabolized through liver and spleen. Conclusions c-Met targeted 68Ga-NODAGA-C21b is a novel small molecule based PET probe for imaging of c-Met overexpression tumors. Its ability to differentiate tumors with high and low c-Met expression in vivo holds the potential for stratification of patients for c-Met targeted cancer therapy. $$graphic_A6B47F64-40EB-4636-AEF2-5EF8FE968326$$

Synthesis and bioevaluation of a novel 99mTc-labeled complex with a crizotinib HYNIC derivative for imaging of c-Met–positive expression

Synthesis and evaluation of 18F labeled crizotinib derivative [18F]FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor

Synthesis and Evaluation of a Novel c-Met-Targeting Cyclic Peptide as a Potential Diagnostic Agent for Colorectal Cancer

Pet Imaging of C-Met in Cancer with Cu-64-Labeled Hepatocyte Growth Factor

Preliminary Application of Micro‐spect/ct Imaging by 99mtc‐tricine‐edda‐hynic‐c‐met for Non‐small‐cell Lung Cancer

68Ga-Labeled Small Molecule Inhibitor for C-Met Targeted Pet Imaging of Tumor.

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

Synthesis and biodistribution of 99Tcm-Cetuximab antibody for lung tumor targeted molecular imaging

(99M)tc-Labeled Dimeric Octreotide Peptide: a Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype 2-Positive Tumors.

Preparation and Evaluation of Tc-99m-Labeled Dimeric Tyr(3)-Octreotide in the Ar42j Tumor Model

Synthesis and preliminary biological evaluation of the 99mTc labeled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers.

Small-Animal Spect/Ct Imaging with 99Mtc-Hynic-h10f Detects Her2 Expression in Mice Bearing Human Breast Cancers

Detection of colorectal cancer using a small molecular fluorescent probe targeted against c-Met

Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.

Radiosynthesis and preclinical evaluation of a 68Ga-labeled tetrahydroisoquinoline-based ligand for PET imaging of C-X-C chemokine receptor type 4 in an animal model of glioblastoma

Synthesis and Biological Evaluation of a Novel 99mtc Cyclopentadienyl Tricarbonyl Complex ([(Cp-R)99mtc(co)3]) for Sigma-2 Receptor Tumor Imaging

Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99m Tc-HYNIC-H10F

SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99Mtc-Hynic-h6f in Breast Cancer Mouse Models.

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Evaluation of a Neurokinin-1 Receptor-Targeted Technetium-99m Conjugate for Neuroendocrine Cancer Imaging

Synthesis and preclinical investigation of 99mTc-p-SCN-Bzl-DTPA-cetuximab for targeting EGFR using head and neck squamous cell carcinoma (HNSCC) xenografts